American science-based longevity company that is dedicated to treating 'Diseases of Aging and Aging as a Disease' with personalised cellular solutions Immorta Bio Inc announced on Friday that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for First in Class Senolytic Immunotherapy SenoVax, intended for the treatment of Advanced Lung Cancer.

The IND, which was granted #30745, is for the commencement of a clinical trial to assess safety, immunogenicity, and efficacy signals of SenoVax in patients with advanced non-small cell lung cancer (NSCLC). The trial is to enrol patients who have failed standard therapies, and will include three patient groups receiving increasing doses of SenoVax.

SenoVax uses dendritic cell technology to supplement the natural ability of the immune system to clear senescent cells. Thomas Ichim, PhD, Immorta Bio president and chief scientific officer, said, 'To our knowledge, this is the first clinical candidate to push the immune system to attack not the cancer itself, but the cells protecting it. In contrast to cancer, which mutates in a very rapid manner, senescent cells surrounding the tumour do not mutate, thus making them a more attractive therapeutic target. While the primary aim of the study is not to investigate systemic effects, it will be of significant interest to observe any additional regenerative benefits of the SenoVax therapy, beyond its impact on tumour size reduction.'